Gilead, J&J Pare Case on Laurus Copy of HIV Drug to Two Patents

Gilead Sciences Inc. and Johnson & Johnson’s Janssen unit dropped claims tied to the only patent they co-own from their lawsuit against Laurus Labs Ltd. over its proposed copy of the HIV treatment Complera.

Judge Zahid N. Quraishi granted the parties’ joint request to dismiss all claims and defenses concerning US Patent No. 10,857,102, which covers Complera’s three-drug formulation, in an order issued Wednesday in the US District Court for the District of New Jersey. The patent expires in January 2033, the latest of the three listed for Complera in the US Food and Drug Administration’s registry of approved ...